top of page
Browse by category
Search
VIVUS launches QSYMIA in the UAE
VIVUS has received market approval of QSYMIA (phentermine and topiramate extended-release capsules) CIV in the United Arab Emirates (UAE)...
The Obesity Society commends FDA's resolution of obesity drug shortages and calls for enforcement against unauthorised compounding
The Obesity Society (TOS) has acknowledged the FDA’s recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and...
ReShape signs distribution agreement in Canada with Liaison Medical for its next-generation Lap-Band 2.0 FLEX
ReShape Lifesciences has signed a distribution agreement with Liaison Medical for distribution of ReShape’s next generation, enhanced...
ANSM clears Allurion to resume sales of the Allurion Balloon in France
Allurion Technologies is relaunching the Allurion Balloon in France after the Agence nationale de sécurité du médicament et des produits...
FDA approves semaglutide to reduce the risk of worsening kidney disease and cardiovascular death
The FDA has approved Ozempic to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease) and death due to...
ReShape Lifesciences provides merger update with Vyome Therapeutics
ReShape Lifesciences and Vyome Therapeutics have provided an update on the definitive merger agreement under which ReShape and Vyome will...
Variant Bio and Novo Nordisk sign multi-year research partnership to discover novel targets for metabolic disease
Variant Bio has announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic...
Rhythm gains expanded indication for IMCIVREE (setmelanotide) for patients as young as 2 years old
Rhythm Pharmaceuticals has received an expanded indication for IMCIVREE (setmelanotide) to include children as young as 2 years old to...
Zepbound (tirzepatide) is the first and only FDA approved prescription medicine for moderate-to-severe OSA in adults with obesity
The FDA has approved Eli Lilly and Company’s Zepbound (tirzepatide) as the first and only prescription medicine for adults with...
BioAge axes STRIDES trial evaluating azelaprag in combination with tirzepatide for the treatment of obesity
BioAge Labs is to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag as monotherapy and in...
Browse by tag
bottom of page